Alumis Inc. ALMS
Updated: 11 Aug 2026
No signal published yet
We already track Alumis and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Alumis Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alumis free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 10, 2026, Alumis reported long-term data from its ONWARD3 study showing that 54% of patients with moderate-to-severe plaque psoriasis achieved complete skin clearance after 48 weeks of envudeucitinib treatment. The company remains on track to submit a New Drug Application to the U.S. FDA in the fourth quarter of 2026.
What Firelda Watch includes for Alumis Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Alumis Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alumis free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more